- Home
- IMNM vs GERN Comparison
IMNM vs GERN Comparison
Compare IMNM & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- GERN
- Stock Information
- Founded
- IMNM 2006
- GERN 1990
- Country
- IMNM United States
- GERN United States
- Employees
- IMNM N/A
- GERN N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- IMNM Health Care
- GERN Health Care
- Exchange
- IMNM Nasdaq
- GERN Nasdaq
- Market Cap
- IMNM 748.3M
- GERN 853.5M
- IPO Year
- IMNM 2020
- GERN 1996
- Fundamental
- Price
- IMNM $8.75
- GERN $1.51
- Analyst Decision
- IMNM Strong Buy
- GERN Buy
- Analyst Count
- IMNM 5
- GERN 7
- Target Price
- IMNM $26.40
- GERN $4.17
- AVG Volume (30 Days)
- IMNM 874.4K
- GERN 11.3M
- Earning Date
- IMNM 08-11-2025
- GERN 08-07-2025
- Dividend Yield
- IMNM N/A
- GERN N/A
- EPS Growth
- IMNM N/A
- GERN N/A
- EPS
- IMNM N/A
- GERN N/A
- Revenue
- IMNM $10,938,000.00
- GERN $116,293,000.00
- Revenue This Year
- IMNM N/A
- GERN $160.12
- Revenue Next Year
- IMNM $349.38
- GERN $55.01
- P/E Ratio
- IMNM N/A
- GERN N/A
- Revenue Growth
- IMNM N/A
- GERN 22264.04
- 52 Week Low
- IMNM $5.15
- GERN $1.17
- 52 Week High
- IMNM $16.81
- GERN $5.06
- Technical
- Relative Strength Index (RSI)
- IMNM 48.43
- GERN 51.36
- Support Level
- IMNM $9.02
- GERN $1.42
- Resistance Level
- IMNM $9.91
- GERN $1.58
- Average True Range (ATR)
- IMNM 0.55
- GERN 0.10
- MACD
- IMNM -0.08
- GERN -0.01
- Stochastic Oscillator
- IMNM 9.37
- GERN 40.00
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.